Even as China and Korea are increasing their share in the $62 billion herbal drugs market worldwide, Indian exporters of ayurvedic drugs are finding it extremely difficult to tap this high-growth segment.
There are a number of big names like Lupin, Cipla, Alkem and J B Chemicals in this area, but exports of herbal or ayurveda medicines from India stand at a tiny $0.25 billion.
Exporters have been strapped by a European Union (EU) stipulation that requires 30 years safe usage data. This effectively prevents the entry of new players from India who also face the possibility of being blacklisted for the presence of heavy metals in their medicines.
Read the remaining story at source: Business Standard